https://www.pharmaceutical-technology.com/data-insights/survodutide-boehringer-ingelheim-international-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/
Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis...
boehringer ingelheimmetabolic dysfunctionsurvodutideinternationalassociated